Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie (NYSE: ABBV) and Neomorph have announced a collaboration and option-to-license agreement to develop molecular glue degraders for oncology and immunology targets. The partnership combines AbbVie's expertise in drug development with Neomorph's molecular glue discovery platform.
Molecular glue degraders represent a novel class of small molecules designed to selectively target and trigger degradation of proteins involved in cancer growth and immune system dysregulation, including previously 'undruggable' proteins.
Under the agreement terms, Neomorph will receive an upfront payment and is eligible for up to $1.64 billion in option fees and milestones, plus tiered royalties on net sales.
Simcere Zaiming and AbbVie (ABBV) have announced a partnership to develop SIM0500, a novel trispecific antibody candidate for multiple myeloma treatment. The drug, currently in Phase 1 clinical trials in China and the U.S., targets GPRC5D, BCMA, and CD3 proteins.
The agreement includes an upfront payment from AbbVie to Simcere Zaiming, with potential milestone payments reaching up to $1.055 billion, plus tiered royalties on net sales outside Greater China. AbbVie will receive tiered royalties on sales within Greater China.
SIM0500, developed using Simcere Zaiming's T-cell engager polyspecific antibody technology platform, has demonstrated strong T cell cytotoxicity against multiple myeloma cells through various antitumor effects.
AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022. The expanded agreement gives AbbVie access to AbCellera's TCE platform for developing therapeutic antibodies targeting tumors.
Under the agreement terms, AbCellera will lead discovery activities while AbbVie retains development and commercialization rights for resulting therapeutic antibodies. AbCellera will receive upfront and research payments, plus potential downstream milestone payments and tiered royalties on net sales.
AbbVie (NYSE: ABBV) and Simcere Zaiming have announced a partnership to develop SIM0500, a novel trispecific antibody for multiple myeloma. The drug candidate, currently in Phase 1 clinical trials in China and the U.S., targets GPRC5D, BCMA, and CD3 using Simcere's T-cell engager polyspecific antibody technology platform.
The agreement includes an upfront payment from AbbVie to Simcere Zaiming, with potential option fees and milestone payments reaching up to $1.055 billion, plus tiered royalties on net sales outside Greater China. AbbVie will receive tiered royalties on sales within the Greater China territory. SIM0500 has demonstrated strong T cell cytotoxicity against multiple myeloma cells through various antitumor effects.
AbbVie (ABBV) and REGENXBIO (RGNX) have announced key updates for their ABBV-RGX-314 clinical program. The companies expect pivotal data on the safety and efficacy of subretinal delivery for wet age-related macular degeneration (wet AMD) patients in 2026 through the ATMOSPHERE® and ASCENT™ trials.
Additionally, both companies will plan a Phase 3 clinical program for diabetic retinopathy (DR) treatment using suprachoroidal delivery via the SCS Microinjector®. This gene therapy aims to address the treatment burden of chronic, frequent dosing in retinal diseases, which are among the leading causes of blindness. ABBV-RGX-314 is being developed as the first potential one-time gene therapy for both wet AMD and DR patients.
AbbVie (ABBV) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, January 15, 2025, at 10:15 a.m. Central time.
Investors and interested parties can access a live audio webcast of the presentation through AbbVie's Investor Relations website at investors.abbvie.com. For those unable to attend the live session, an archived version will be made available later the same day.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has launched its third annual CoolMonth campaign featuring CoolSculpting® Elite, the leading non-surgical fat reduction treatment. The promotion includes two key offers: a $300 discount for first-time patients valid through February 6, 2025, and a sweepstakes opportunity to win $10,000 for patients who get treated by March 24, 2025.
To participate, customers must join Allē, Allergan Aesthetics' free loyalty program. CoolSculpting® Elite is FDA-cleared for treating visible fat bulges in various body areas, including thigh, abdomen, flank, bra fat, back fat, under buttocks, and upper arm for patients with specific BMI requirements.
AbbVie (NYSE: ABBV) has announced it will release its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before market opening. The company will host a live webcast earnings conference call at 8 a.m. Central time, which will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived version of the session will be made available later that day.
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Nimble Therapeutics for $200 million in cash, with additional potential milestone-based payments. The acquisition includes Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease (IBD), along with other novel oral peptide candidates for autoimmune diseases.
The deal also encompasses Nimble's proprietary peptide synthesis, screening, and optimization platform, which accelerates the discovery and optimization of peptide candidates. The IL23R inhibitor targets a clinically validated therapeutic pathway in autoimmune diseases, particularly affecting psoriasis and IBD pathogenesis through increased inflammation and amplified immune responses.
AbbVie (ABBV) has completed its acquisition of Aliada Therapeutics, strengthening its neuroscience pipeline with ALIA-1758, a potential best-in-class disease-modifying therapy for Alzheimer's disease currently in Phase 1 clinical trials. The acquisition brings two key assets: the anti-pyroglutamate amyloid beta antibody ALIA-1758, and a novel blood-brain barrier (BBB)-crossing technology that enhances delivery of targeted drugs into the central nervous system. This strategic move positions AbbVie to address the growing challenge of Alzheimer's disease, which affects millions globally and is becoming more prevalent with aging populations.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
